Patents by Inventor Nigel Robert Arnold Beeley
Nigel Robert Arnold Beeley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180185325Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.Type: ApplicationFiled: June 8, 2016Publication date: July 5, 2018Applicant: Thesan Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
-
Publication number: 20180179174Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.Type: ApplicationFiled: June 6, 2016Publication date: June 28, 2018Applicant: Thesan Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
-
Publication number: 20180118707Abstract: The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.Type: ApplicationFiled: June 7, 2016Publication date: May 3, 2018Applicant: Thesan Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Howard Glenn Welgus, Jay Edward Birnbaum, J. Gordon Foulkes, Celia Patricia Jenkinson, Jean Hilaire Saurat
-
Publication number: 20160324804Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: ApplicationFiled: July 22, 2016Publication date: November 10, 2016Applicant: PhilEra New Zealand LimitedInventors: Garth James Smith Cooper, John Richard Baker, Nigel Robert Arnold Beeley
-
Publication number: 20150164826Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: ApplicationFiled: December 17, 2014Publication date: June 18, 2015Applicant: PhilEra New Zealand LimitedInventors: Garth James Smith Cooper, John Richard Baker, Nigel Robert Arnold Beeley
-
Patent number: 8263550Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would benefit by lower plasma glucose and delaying and/or slowing gastric emptying.Type: GrantFiled: December 2, 2010Date of Patent: September 11, 2012Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett
-
Patent number: 7960341Abstract: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.Type: GrantFiled: September 8, 2006Date of Patent: June 14, 2011Assignee: Amylin Pharmaceuticals, Inc.Inventors: David R. Hathaway, Nigel Robert Arnold Beeley, Kathryn Susan Prickett, Andrew A. Young
-
Publication number: 20110071076Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would benefit by lower plasma glucose and delaying and/or slowing gastric emptying.Type: ApplicationFiled: December 2, 2010Publication date: March 24, 2011Applicant: AMYLIN PHARMACEUTICALS, INC.Inventors: Nigel Robert Arnold BEELEY, Kathryn Susan Prickett
-
Patent number: 7858740Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would be benefited by lower plasma glucose and delaying and/or slowing gastric emptying.Type: GrantFiled: August 28, 2006Date of Patent: December 28, 2010Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett
-
Patent number: 7700549Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: August 29, 2008Date of Patent: April 20, 2010Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew Young
-
Patent number: 7696161Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.Type: GrantFiled: May 25, 2007Date of Patent: April 13, 2010Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett
-
Publication number: 20090176704Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: ApplicationFiled: August 29, 2008Publication date: July 9, 2009Applicant: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew Young
-
Patent number: 7544690Abstract: The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.Type: GrantFiled: September 30, 2002Date of Patent: June 9, 2009Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Yoshinori Sekiguchi, Kosuke Kanuma, Katsunori Omodera, Thuy-Anh Tran, Bryan Aubrey Kramer, Nigel Robert Arnold Beeley
-
Publication number: 20090029913Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.Type: ApplicationFiled: March 28, 2007Publication date: January 29, 2009Applicant: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett
-
Patent number: 7419952Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: March 3, 2006Date of Patent: September 2, 2008Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew A. Young
-
Publication number: 20080119393Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.Type: ApplicationFiled: May 25, 2007Publication date: May 22, 2008Applicant: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn Susan Prickett
-
Patent number: 7297761Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Type: GrantFiled: July 19, 2004Date of Patent: November 20, 2007Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew Young, Bronislava Gedulin
-
Patent number: 7223725Abstract: The present invention relates to novel exendin agonist compounds useful in treatment of Type I and II diabetes, and useful in lowering plasma glucose levels, reducing body weight, and delaying and/or slowing gastric emptying.Type: GrantFiled: November 13, 1998Date of Patent: May 29, 2007Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn Susan Prickett
-
Patent number: 7157555Abstract: Novel exendin peptide compounds are provided.Type: GrantFiled: August 6, 1998Date of Patent: January 2, 2007Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn Susan Prickett
-
Patent number: 7138375Abstract: Provided are methods for lowering plasma lipid in an individual in need of or desirous of lowering plasma lipid by administering an amount of an exendin or an exendin agonist analog effective to lower plasma lipid.Type: GrantFiled: October 14, 2004Date of Patent: November 21, 2006Assignee: Amylin Pharmaceuticals, Inc.Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew Young